..."HER-Vaxx is safe and provides relevant clinical benefit...

First 54 Last

Share
Profile

Follow
DTshares

1,046 Posts.

445

22/01/23

13:59

Post #: 65817720
Share

Originally posted by Dosdogs: ↑

Hi @LHI 14 I’m a bit late to this discussion but your post caused me to revisit HerVaxx results. It appears that IMU regard existing trial patients as censored which is unusual because normally censored pts have left the trial. That a ‘median’ result should shift when the median has already occurred is also unusual. What I noticed was the relative shift in censored pts from the 2 graphs you posted. It appears that the pt at about 16 mths has succumbed at about 19 mths but notice that another pt has been censored at about 4 mths. That pt needs to stay above ground for the 14 mths or the stats will go backwards. The bigger reason for my post is the footnote that states 5 pts went on herceptin, that was totally new info for me and I wonder if this sullies the results given IMU 131 is meant to replace herceptin.

In any event, perhaps contrary to some, I’m happy to discount hervaxx to 0 and have all appendages crossed for CF33. Go IMU (but pls stop blowing smoke where it doesn’t belong)!

Expand

..."HER-Vaxx is safe and provides relevant clinical benefit overstandard of care chemotherapy. Clinical trial information: NCT02795988. Research Sponsor: ImugeneLimited."...

Lol, imagine being an internet troll to make a living while others are doing real science and investing for progress.

IMU Price at posting: 15.5¢ Sentiment: Buy Disclosure: Held
20 Upvote

0 Great analysis

Reply